Christopher Frankenfield
2023
In 2023, Christopher Frankenfield earned a total compensation of $1.9M as Chief Operating Officer at Xilio Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $210,000 |
|---|---|
| Option Awards | $1,156,022 |
| Salary | $481,108 |
| Other | $13,740 |
| Total | $1,860,870 |
Frankenfield received $1.2M in option awards, accounting for 62% of the total pay in 2023.
Frankenfield also received $210K in non-equity incentive plan, $481.1K in salary and $13.7K in other compensation.
Rankings
In 2023, Christopher Frankenfield's compensation ranked 584th out of 2,978 executives tracked by ExecPay. In other words, Frankenfield earned more than 80.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 584 out of 2,978 | 80th |
Division Manufacturing | 333 out of 1,637 | 80th |
Major group Chemicals And Allied Products | 231 out of 906 | 75th |
Industry group Drugs | 228 out of 869 | 74th |
Industry Pharmaceutical Preparations | 143 out of 627 | 77th |
Source: SEC filing on April 25, 2024.
Frankenfield's colleagues
We found three more compensation records of executives who worked with Christopher Frankenfield at Xilio Therapeutics in 2023.